

- 34 Bai R, Taylor GF, Cichacz ZA, Herald CL, Kepler JA, Pettit GR, et al. *Biochemistry* 1995;**34**:9714.
- 35 Uckun FM. *Curr Pharm Des* 2001;**7**:1627.
- 36 Dorléans A, Gigant B, Ravelli RBG, Mailliet P, Mikol V, Knossow M. *Proc Natl Acad Sci U S A* 2009;**106**:13775.
- 37 For a review of tubulin inhibitors that interact with the colchicine binding site, see Lu Y, Chen J, Xiao M, Li E, Miller DD. *Pharm Res* 2012;**29**:2943.
- 38 Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC. *Cancer Res* 2002;**62**:3711.
- 39 Hsieh HP, Liou JP, Mahindroo N. *Curr Pharm Des* 2005;**11**:1655.
- 40 Cirila A, Mann J. *Nat Prod Rep* 2003;**20**:558.
- 41 Hadimani MB, Hua J, Jonklaas MD, Kessler RJ, Sheng Y, Olivares A, et al. *Bioorg Med Chem Lett* 2003;**13**:1505.
- 42 Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, et al. *Br J Cancer* 2010;**102**:1355.
- 43 <http://clinicaltrials.gov/ct2/results?term=AVE8062>.
- 44 Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, et al. *Lung Cancer* 2013;**81**:422.
- 45 Galmarini CM. *Curr Opin Invest Drugs* 2005;**6**:623.
- 46 Yee KWL, Hagey A, Verstovsek S, Cortes J, García-Manero G, O'Brien SM, et al. *J Clin Cancer Res* 2005;**11**:6615.
- 47 Shan B, Medina JC, Santha E, Frankmoelle WP, Chou T-C, Learned RM, et al. *Proc Natl Acad Sci U S A* 1999;**96**:5686.
- 48 For a review of diketopiperazine-derived antimicrotubule/vascular disrupting agents, see Hayashi Y, Yamazaki-Nakamura Y, Yakushiji F. *Chem Pharm Bull* 2013;**61**:889.
- 49 <http://clinicaltrialsfeeds.org/clinical-trials/results/term=Indibulin>.
- 50 Kim LJ, Chamberlain MC, Zhu J, Raizer JJ, Grimm SA, Phuphanich S, et al. *J Clin Oncol* 2011;**29** (Suppl.):2088.
- 51 <http://www.australiancancertrials.gov.au/search-clinical-trials/search-results/clinical-trials-details.aspx?TrialID=82702&ds=1>.
- 52 Ricart A, Ashton E, Cooney M, Sarantopoulos J, Brell J, Feldman M, et al. *Cancer Chemother Pharmacol* 2011;**68**:959.
- 53 Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD. *Cancer Invest* 2002;**20**:192.
- 54 Desbène S, Giorgi-Renault S. *Curr Med Chem Anticancer Agents* 2002;**2**:71.
- 55 (a) Lakhani NJ, Sarkar MA, Venitz J, Figg WD. *Pharmacotherapy* 2003;**23**:165; (b) Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, et al. *Gynecol Oncol* 2009;**115**:90.
- 56 Pasquier E, Sinnappan S, Muñoz MA, Kavallaris M. *Mol Cancer Ther* 2010;**9**:1408.
- 57 Malika S, Cusidó R, Mirjalilic MH, Moyano E, Palazón J, Bonfill M. *Process Biochem* 2011;**46**:23.
- 58 Guéritte F. *Curr Pharm Des* 2001;**7**:1229.
- 59 Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. *J Control Release* 2003;**91**:417.
- 60 Bissery MC. *Curr Pharm Des* 2001;**7**:1251.
- 61 Gurtler JS, Von Pawel J, Spiridonidis CH, Grossi F, Larriba JL, Moscovici M, et al. *J Clin Oncol* 2004;**22**:7136.
- 62 Broker LE, De Vos FY, Gall H, Gietema JA, Voi M, Cohen MB, et al. *J Clin Oncol* 2004;**22**:2029.
- 63 For a review of cabazitaxel, see Paller CJ, Antonarakis ES. *Drug Des Dev Ther* 2011;**5**:117.
- 64 Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, et al. *Oncology* 2013;**85**:208.
- 65 Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. *Cancer Chemother Pharmacol* 2011;**68**:1565.
- 66 Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, et al. *Cancer Chemother Pharmacol* 2008;**61**:453.
- 67 <http://www.cancer.gov/clinicaltrials/search/view?cdrid=597371&version=HealthProfessional>.
- 68 Nicolaou KC, Valiulin RA. *Org Biomol Chem* 2013;**11**:4154.